A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03214757|
Recruitment Status : Not yet recruiting
First Posted : July 12, 2017
Last Update Posted : January 10, 2018
Dilated cardiomyopathy is a heart muscle disorder characterized by systolic dysfunction and dilation of the left or both ventricles.Dilated cardiomyopathy can develop in people of any age or ethnicity, although it is more common in male than female persons occurring at a ratio of about three to one in male to female persons.
Dilated cardiomyopathy is the predominant cause of cardiomyopathy in pediatric populations. Annual incidence in pediatric populations has been reported to be much lower than one to one hundred seventy thousand in the United States and one to one hundred forty thousand in Australia.
Although pediatric dilated cardiomyopathy has a lower annual incidence than adult dilated cardiomyopathy, the outcome for pediatric dilated cardiomyopathy patients is particularly severe.
Dilated cardiomyopathy is the most frequent cause of heart transplantation in pediatric patients. Data from international pediatric dilated cardiomyopathy registries indicate that the rates of death or heart transplantation over one and five year periods were thirty one percent and forty six percent, respectively.
Onset of dilated cardiomyopathy is usually insidious but may be acute in as many at twenty five percent of patients. Approximately fifty percent of patients with dilated cardiomyopathy have a history of preceding viral illness.
|Condition or disease||Intervention/treatment|
|Pediatric Dilated Cardiomyopathy||Other: treatment of anemia.|
The clinical diagnosis of dilated cardiomyopathy is made from history, physical examination, and noninvasive testing. The initial clinical manifestations of dilated heart failure are generally those of respiratory distress secondary to congestion of the pulmonary and systemic venous circulations.
Pallor, irritability, diaphoresis, tachypnea, easy fatigability are characteristics.
Failure to grow may also occur. In older patients, a history of orthopnea, nocturnal cough, and dyspnea provoked by minimal activity can be elicited and generally precede evidence of systemic venous congestion. In rapidly progressive disease, dominant symptoms are often abdominal distention, right upper quadrant pain, and nausea. Less often, initial symptoms in childhood include arrhythmias, syncope, neurologic problems (seizures or delayed development), vomiting, abdominal distention, or fever.
Although as many as fifty percent of children with cardiomyopathy and heart failure give a history of a nonspecific febrile illness within three months of presentation, no evidence of myocarditis can usually be found on biopsy.'Physical signs vary with the stage of the disease.
Signs of congestive heart failure are frequent, and include tachypnea,tachycardia, diaphoresis, hepatomegaly, pallor, and, in advanced cases, hypotension and shock.
Failure to thrive may be present if, heart failure has been long standing. Patients are generally not cyanotic. Wheezing may be heard; however, rales are infrequent, especially in infants.
Neck vein distension is common, the external jugular crest reflecting mean right atrial pressure, the internal jugular exhibiting a prominent V wave indicative of tricuspid regurgitation.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy|
|Estimated Study Start Date :||February 2018|
|Estimated Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||December 2018|
|group with dilated cardiomyopathy without anemia|
|group with dilated cardiomyopathy with anemia||
Other: treatment of anemia.
drug treatment of anemia.
- Heart failure [ Time Frame: four months duration after start of the study ]Through clinical manifestations of heart of heart failure and echocardiographic assesment of ventricular function
- Quality of Well-Being Scale [ Time Frame: three months duration after start of the study ]To measure health related quality of life, to monitor the health of populations over time, or to evaluate the efficacy and effectiveness of clinical therapies of practices using a preference weighted self administered measure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03214757
|Contact: Nagwa Ali Mohammed, MD||0201096260950||Namma65@yahoo.com|
|Contact: Osama Mahmoud El-Asheer, MD||0201001348864||Asheer1970@gmail.com|